Glucagon-Like Peptide-1 (GLP-1) Agonist / 대한내과학회지
Korean Journal of Medicine
;
: 9-13, 2014.
Article
Dans Coréen
| WPRIM
| ID: wpr-69100
ABSTRACT
The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications. Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus. The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Prévalence
/
Diabète de type 2
/
Glucagon-like peptide 1
/
Incrétines
/
Glucose
/
Insuline
Type d'étude:
Étude de prévalence
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Korean Journal of Medicine
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS